PatientsVille.com Logo


Everolimus Medical Research Studies

Up-to-date List of Everolimus Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Everolimus Medical Research Studies

Rank Status Study
1 Recruiting Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer
Condition: Advanced Cancer
Interventions: Drug: Sirolimus;   Drug: Vorinostat;   Drug: Everolimus;   Drug: Temsirolimus
Outcome Measures: Maximum Tolerated Dose (MTD);   Tumor Response
2 Not yet recruiting Study of Everolimus (RAD001, Afinitor®) for Children With Recurrent or Progressive Ependymoma
Condition: Recurrent Childhood Ependymoma
Intervention: Drug: Everolimus
Outcome Measures: Objective Response Rate (Complete Response Rate and Partial Response Rate) following treatment with Everolimus for children with recurrent or progressive ependymomas.;   Duration of response following treatment with Everolimus for children with recurrent or progressive ependymomas.;   Progression free survival (PRS) following treatment with Everolimus for children with recurrent or progressive ependymomas.;   Event free survival (EFS) following treatment with Everolimus for children with recurrent or progressive ependymomas.;   Number of Participants with Adverse Events as a Measure of Safety and Tolerability.;   Correlation of tumor Objective Response Rate to established immunohistochemical biomarkers of mTOR pathway activation, including pS6, p4EBP1, pPRAS40, pp70S6K and PTEN.
3 Recruiting Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and Exemestane
Condition: Metastatic Breast Cancer
Intervention: Drug: Everolimus
Outcome Measures: progression free survival;   overall survival;   clinical benefit Rate(CBR);   chemo-free interval;   safety by toxicity;   compliance;   biological marker
4 Recruiting Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer
Conditions: Advanced Cancer;   Solid Tumor
Interventions: Drug: Vemurafenib;   Drug: Everolimus;   Drug: Temsirolimus
Outcome Measure: Maximum Tolerated Dose (MTD) of combination Vemurafenib
5 Recruiting Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)
Condition: Sturge Weber Syndrome
Intervention: Drug: Everolimus
Outcome Measures: Evaluate the clinical effectiveness of Everolimus as an adjunct treatment to reduce the seizure activity;   Clinical progression of facial and/or body port-wine hemangioma;   Clinical progression of glaucoma
6 Recruiting Differentiating Everolimus Versus Sirolimus in Combination With Calcineurin Inhibitors in Kidney Transplant Patients
Condition: Kidney Transplantation
Interventions: Drug: Everolimus;   Drug: Sirolimus
Outcome Measures: Creatinine Outcome Measure (1);   Calculated Glomerular Filtration Rate (1);   Calculated Glomerular Filtration Rate (2);   Kidney Injury Molecule-1 (1);   Kidney Injury Molecule-1 (2);   S-Adenosylhomocysteine Hydrolase (1);   S-Adenosylhomocysteine Hydrolase (2);   S-Adenosylmethionine (1);   S-Adenosylmethionine (2);   Creatinine Outcome Measure (2);   12-Hydroxyeicosatetraenoic acid (1);   12-Hydroxyeicosatetraenoic acid (2);   20-Hydroxyeicosatetraenoic acid (1);   20-Hydroxyeicosatetraenoic acid (2);   18-​Hydroxyeicosapentaenoic acid (1);   18-​Hydroxy-​eicosapentaenoic acid (2);   Ornithine (1);   Ornithine (2);   Arginine (1);   Arginine (2)
7 Recruiting Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer
Condition: Hormone Receptor Positive Breast Cancer
Interventions: Drug: Everolimus;   Drug: Letrozole;   Drug: Exemestane;   Drug: Alcohol-free dexamethasone mouth rinse
Outcome Measures: Percentage of patients progression-free after completion of 1st line treatment (Everolimus + letrozole);   Overall response rate and clinical benefit rate in patients receiving the first line study treatment (Everolimus + letrozole);   Percentage of patients progression-free after completion of 2nd line treatment (Everolimus + exemestane);   Overall survival of patients receiving first line study treatment (Everolimus + letrozole);   Reduction in severity and duration of oral stomatitis;   Assessment of safety based on the frequency of adverse events that fall outside normal pre-specified ranges;   Overall response rate and clinical benefit rate in patients receiving the second line study treatment (Everolimus + exemestane)
8 Recruiting Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: RAD001 Afinitor Everolimus;   Drug: RAD001 gemcitabine;   Drug: RAD001 cisplatin
Outcome Measures: The recommended dose of the combination of gemcitabine, cisplatin and RAD001 (Everolimus) in patients with metastatic triple-negative breast cancer;   Efficacy of gemcitabine and cisplatin with or without RAD001 in patients with metastatic triple-negative breast cancer by evaluating progression free survival (PFS);   The maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of gemcitabine/cisplatin/RAD001;   number of patients with adverse events as a measure of safety and tolerability;   objective response rate;   Overall survival (OS);   check biomarkers associated with the response of RAD001: angiogenesis, metabolism, immune cells profiles
9 Not yet recruiting Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease
Condition: Liver Cancer
Interventions: Other: TheraSphere;   Drug: Everolimus;   Other: Phone Call
Outcome Measure: Dose Limiting Toxicities (DLT) for Combination of TheraSphere and Everolimus
10 Recruiting Comparing Everolimus and Sirolimus in Renal Transplant Recipients
Condition: Renal Failure
Interventions: Drug: Everolimus;   Drug: Sirolimus
Outcome Measure: Graft Survival Comparison of Zortress vs. Rapamune
11 Not yet recruiting Study of Safety and Efficacy of BYL719 With Everolimus or BYL719 With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
Conditions: Neoplasms,;   Breast Neoplasms,;   Kidney Neoplasms,;   Pancreatic Neuroendocine Neoplasms
Interventions: Drug: BYL719;   Drug: Everolimus;   Drug: Exemestane
Outcome Measures: Dose escalation : Incidence of dose Limiting Toxicity (DLTs);   Dose expansion: Number of patients with adverse events as a measure of safety and tolerability;   Dose escalation: Number of patients with adverse events as a measure of safety and tolerability;   Dose escalation : BYL719, Everolimus and Exemestane (when applicable) Plasma concentrations;   Dose escalation : BYL719, Everolimus drug-drug interaction;   Dose expansion: Progression free survival;   Dose expansion : Duration of Response;   Dose expansion: Clinical benefit Rate;   Dose expansion: Overall response rate
12 Recruiting Calcineurin-inhibitor Elimination/Reduction Randomized to Everolimus/Myfortic® vs Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction
Condition: Renal Transplant
Interventions: Drug: Arm 1 Everolimus/myfortic®;   Drug: Arm 2 Everolimus/Reduced dose tacrolimus
Outcome Measures: Renal function;   Graft survival;   Biopsy proven acute rejection;   Patient survival;   Impaired glucose tolerance;   Proteinuria;   Lipid levels;   Mouth ulcers;   Gastrointestinal complaints;   Leukopenia;   Thrombocytopenia;   Neurotoxicity;   Pneumonitis;   Cytomegalovirus;   Infection requiring hospitalization;   BK infection;   BK nephropathy;   Malignancies;   Cardiovascular complications;   Development of donor specific antibody
13 Recruiting Anakinra or Denosumab and Everolimus in Advanced Cancer
Condition: Advanced Cancers
Interventions: Drug: Everolimus;   Drug: Anakinra;   Drug: Denosumab
Outcome Measure: Maximum Tolerated Dose (MTD)
14 Not yet recruiting A Phase II Study of Everolimus in Patients With Primary or Relapsed Chondrosarcomas
Condition: Chondrosarcoma
Interventions: Drug: Everolimus 2.5 mg/day;   Drug: Everolimus 10 mg/day
Outcome Measures: Success Rate obtained per arm;   Progression-Free Survival (PFS);   Safety;   Overall Survival;   Quality of Life
15 Recruiting Vandetanib With Everolimus
Condition: Advanced Cancers
Interventions: Drug: Vandetanib;   Drug: Everolimus
Outcome Measure: Maximum Tolerated Dose (MTD) of Vandetanib with Everolimus
16 Recruiting A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer
Condition: Advanced Solid Tumors, Non-small Cell Lung Cancer
Intervention: Drug: AMG 479, Everolimus, Panitumumab
Outcome Measures: To define the maximal tolerated dose (MTD) and/or recommended phase II dose (RPTD) for the doublet AMG 479 in combination with Everolimus in subjects with advanced solid tumors.;   To define the maximal tolerated dose (MTD) and/or recommended phase II dose (RPTD) for the triplet AMG 479 in combination with Everolimus and panitumumab in subjects with advanced solid tumors.;   To describe the toxicity profile seen with these combinations.;   To describe any signs of clinical activity, including response rate and progression free survival associated with these regimens.
17 Recruiting Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI
Condition: Metastatic Breast Cancer
Interventions: Drug: Fulvestrant;   Drug: Everolimus;   Drug: Placebo (for Everolimus)
Outcome Measures: Progression-free survival;   Participant Adverse Events as a Measure of Safety and Tolerability;   Objective Response Rate;   Time to Progression;   Overall Survival
18 Recruiting Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex
Conditions: Tuberous Sclerosis Complex;   TSC Related Cognitive Disability;   TSC Related Autism;   TSC Related Learning Problems
Interventions: Drug: Everolimus;   Drug: Placebo
Outcome Measures: Cognitive ability measured by IQ;   Autistic features;   Social and communicational skills;   Working memory and attention, information processing;   Visual-motor integration;   Child behavior;   Executive functioning;   Sleeping problems;   Child health;   Sensory related difficulties;   Epilepsy
19 Recruiting A Study of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for Locally Advanced Cervix Cancer
Condition: Locally Advanced Cervical Cancer
Intervention: Drug: Everolimus
Outcome Measures: The toxicity criteria will be evaluated according to National Cancer Institute - Common Toxicity Criteria for Adverse Events (NCI-CTCAE), version 3.0.;   The objective response rate will be evaluated according to clinical/gynecological examination and inconformity with the RECIST criteria (Response Evaluation Criteria in Solid Tumors, version 1.1)
20 Not yet recruiting Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
Conditions: Breast Cancer;   Solid Tumors
Interventions: Drug: Everolimus;   Drug: Trastuzumab;   Drug: Letrozole
Outcome Measures: Maximum Tolerated Dose (MTD) of Everolimus, Letrozole and Trastuzumab;   Clinical Benefit Rate (CBR)

These studies may lead to new treatments and are adding insight into Everolimus etiology and treatment.

A major focus of Everolimus research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Everolimus